ProMIS Neurosciences, a clinical-stage biotech company focused on antibody therapeutics for neurodegenerative diseases, announced its participation in several healthcare conferences throughout November 2026. CEO Neil Warma will deliver presentations and fireside chats at events including the Guggenheim Healthcare Innovation Conference, Stifel Healthcare Conference, UBS Global Biopharma Conference, and others. The company will also present interim safety and biomarker data for its Alzheimer’s drug candidate PMN310 at the Clinical Trials on Alzheimer’s Disease conference. These events provide ProMIS an opportunity to update investors and the healthcare community on its progress and pipeline developments.
ProMIS Neurosciences' upcoming conference participation is presented here with a snapshot of Pluang's health sector market as of Nov 05, 2026 19:01 WIB. Out of 150 health-sector US stocks, 94 rose and 48 fell today. Among notable movers, ADMA Biologics Inc surged 19.56% to USD 12.53 with a typical hold time of 20 days and 100% sell order activity, contrasting with Becton Dickinson and Co which dropped 6.86% to USD 194.84 and a much longer hold time of 105 days, while Revolution Medicines Inc rose 7.14% to USD 213.95 with a 10-day hold time.
Global tech giants like Amazon, Google, and Microsoft are committing hundreds of billions of dollars to expand AI-focused data center accelerators, driven by surging demand from generative AI workloads that exceed traditional CPU capabilities. These ...
Berkshire Hathaway's stock portfolio is now worth about three times what the company originally paid for it. These gains alone represent roughly 19% of Berkshire Hathaway's total company value, highlighting the significant growth and value generated ...
C3is Inc. will implement a one-for-five reverse stock split effective November 9, 2026, reducing its outstanding shares from about 4.2 million to 0.84 million. This move aims to increase the stock price to meet Nasdaq's minimum bid price requirement ...
Firmly secured $15 million in a Series A funding round led by Squarepoint Capital, with participation from J.P. Morgan Payments, Mastercard, and Samsung NEXT. The company provides a no-code platform that connects merchants to AI-driven shopping chann...
On November 4, 2026, Shell plc repurchased a total of 1,876,276 shares across multiple trading venues including LSE, Chi-X, BATS, XAMS, CBOE, and TQEX. The shares were bought at prices ranging from £37.98 to £38.82 and €45.70 to €46.72, with an avera...
